Serious Fraud Office launches criminal inquiry into GlaxoSmithKlineBMJ 2014; 348 doi: https://doi.org/10.1136/bmj.g3612 (Published 29 May 2014) Cite this as: BMJ 2014;348:g3612
- Adrian O’Dowd
The United Kingdom’s major fraud body has launched a criminal investigation into the drug company GlaxoSmithKline (GSK). The Serious Fraud Office inquiry, announced on 27 May, will focus on the commercial practices of GSK and its subsidiaries and comes just weeks after the company was accused of bribery in China.1
The BMJ understands that the new investigation will look at …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial